### UK Biobank (UKBB)の条文と対応するEGAおよびNIHの条文

* **UKBBの条文（英）:** 10.1 The parties agree that: 10.1.1 subject to clauses 10.2, 10.3 and 10.4, UK Biobank’s maximum aggregate Liability under this MTA and/or in relation to the Approved Research Project shall be limited to the Access Charges paid or payable by the Applicant to UK Biobank (whether or not invoiced to the Applicant) in relation to the Approved Research Project; and 10.1.2 subject to clauses 10.2, 10.3 and 10.5, the Applicant's maximum aggregate Liability under this MTA and/or in relation to the Approved Research Project shall be limited to the Access Charges paid or payable by the Applicant to UK Biobank (whether or not invoiced to the Applicant) in relation to the Approved Research Project.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** 4. Limitation of Liability [May consider including a cap on liability/damages].
        * **比較結果:** 部分一致
        * **判断理由（日）:** NIHの条文は責任制限（Limitation of Liability）に関する条項を示唆しているが、具体的な内容は提供されていないため、UKBBの具体的な責任制限と完全に一致するかは不明である。ただし、主題は一致しているため、部分一致とした。

* **UKBBの条文（英）:** 10.2 Notwithstanding clause 10.1 above, UK Biobank shall have no Liability to the Applicant and the Applicant shall have no Liability to UK Biobank for any: 10.2.1 loss of profit (whether direct, indirect or consequential); 10.2.2 loss of use, loss of revenue, loss of production or loss of business (in each case whether direct, indirect or consequential); 10.2.3 loss of goodwill, loss of reputation or loss of opportunity (in each case whether direct, indirect or consequential); 10.2.4 loss of anticipated savings or loss of margin (in each case whether direct, indirect or consequential); 10.2.5 loss of use or value of any data or software (in each case whether direct, indirect or consequential); or 10.2.6 indirect or consequential loss.
    * **対応するEGAの条文（英）:** 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipients use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data.
        * **比較結果:** 部分一致
        * **判断理由（日）:** EGAの条文は、データプロデューサーの責任範囲と保証の免責を定めており、「loss of profit」を含む「losses」に対する責任を除外している点でUKBBと類似している。しかし、EGAは「データの正確性や品質」にも言及しており、完全に一致するわけではないため、部分一致とした。
    * **対応するNIHの条文（英）:** 4. Limitation of Liability [May consider including a cap on liability/damages].
        * **比較結果:** 部分一致
        * **判断理由（日）:** NIHの条文は責任制限について言及しているが、UKBBの条文のように特定の種類の損失（例：利益の損失、信用の損失）を具体的に列挙していないため、部分一致とした。

* **UKBBの条文（英）:** 10.3 Nothing in this MTA shall operate to exclude or limit any Liability which cannot legally be limited including but not limited to liability for: 10.3.1 death or personal injury caused by negligence; 10.3.2 for its fraud or fraudulent misrepresentation; and 10.3.3 for any matter for which it is not permitted by law to exclude or limit, or to attempt to exclude or limit, its Liability.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 10.4 For the avoidance of doubt, UK Biobank shall have no responsibility or Liability (including but without limitation any product-related Liability) for any finding, product, test or treatment developed directly or indirectly by the Applicant using the Materials.
    * **対応するEGAの条文（英）:** 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipients use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data.
        * **比較結果:** 部分一致
        * **判断理由（日）:** EGAの条文は、データプロデューサーがデータの正確性や品質について責任を負わないことを明確にしている。これは、UKBBの条文がUK Biobankが申請者の研究成果物に対して責任を負わないことを述べている点と主題が類似しているため、部分一致とした。
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 10.5 Nothing in this MTA shall operate to exclude or limit the Applicant’s Liability to UK Biobank for any loss, damage, costs or expenses arising from: 10.5.1 the Applicant’s failure to comply with clause 9 (Data Protection) and clauses 14.5 to 14.10 inclusive (Third-Party Processors); 10.5.2 any breach of clause 2.2 or any circumstance in which the Applicant sub-licenses, distributes or otherwise shares the Materials (including any IPRs) with any unauthorised person or third party; 10.5.3 any circumstance set out in clauses 4.5 and 4.7; and 10.5.4 any Data Security Incident which is caused by the Applicant.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 11.1 The term of this MTA shall commence on the Effective Date and shall end on the Completion Date unless terminated sooner in accordance with clause 12 or in accordance with law.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** 8.a. Term: The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as set forth in this Section 8, shall remain in effect [may consider a specified term; e.g., set number of years, or a broader end date, e.g., until completion of the Research].
        * **比較結果:** 一致
        * **判断理由（日）:** 両方の条文は、契約期間が発効日から始まり、特定の終了日または条件まで有効であることを規定している。

* **UKBBの条文（英）:** 11.2 The Term of this MTA may be extended by the Applicant (and with the agreement of UK Biobank) during the final year of the Approved Research Project in the following one (1) year increments: 11.2.1 for a minimum of period of one (1) year; 11.2.2 for a period of two (2) years; or 11.2.3 for a maximum period of three (3) years; on application to UK Biobank setting out (in reasonable detail) the reasons for the extension request and subject to the payment of the relevant further Access Charges.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 11.3 For the avoidance of doubt, the extensions set out in clause 11.2 above can be applied cumulatively (subject to applicable Access Charges) so that, for example, an extension of 3 years may be granted to take the Approved Research Project duration from 3 years to 6 years, and this may then be extended by a further 3 years to 9 years and so on.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 12.1 UK Biobank shall be entitled to terminate this MTA immediately by written notice to the Applicant if the Applicant: 12.1.1 commits any breach of a material provision of this MTA or a material breach of this MTA, and, in the case of a breach capable of remedy, fails to remedy the same within 10 days after receipt of a written notice giving particulars of the breach and requiring it to be remedied; or 12.1.2 ceases, is likely to cease, or threatens to cease carrying on business or suffers an Insolvency Event, or is subject to a serious, adverse regulatory finding.
    * **対応するEGAの条文（英）:** 15. XXXXX may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements.
        * **比較結果:** 部分一致
        * **判断理由（日）:** 両方の条文は、データ提供者（UK BiobankまたはEGA）が書面通知により契約を終了できることを規定している。しかし、UKBBは特定の違反事由（重大な違反、事業停止など）を詳細に列挙しているのに対し、EGAは「いかなる理由であれ（for any reason）」という表現を使用している。この詳細な内容の違いから部分一致とした。
    * **対応するNIHの条文（英）:** 8.b. Termination: Either party may terminate this Agreement upon [insert number] days prior written notice to the other party for any reason or no reason. Registry may terminate this Agreement immediately upon written notice to Researcher if Registry is no longer permitted to share the Data with Researcher. In addition, either party may terminate this Agreement upon written notice to the other party in the event of a material breach of this Agreement by the other party, which material breach is not cured within [insert number] days after receipt of written notice thereof.
        * **比較結果:** 一致
        * **判断理由（日）:** 両方の条文は、重大な違反があった場合に書面通知により契約を終了できることを規定している。NIHは「重大な違反が[日数]以内に是正されない場合」という表現を使用しており、UKBBの「10日以内に是正されない場合」と非常に類似しているため、一致とした。

* **UKBBの条文（英）:** 12.2 Upon expiry of the MTA pursuant to clause 11.1 above or termination of this MTA by UK Biobank pursuant to clause 12.1 or in accordance with law: 12.2.1 the grant of rights and all licences to the Applicant under this MTA shall be automatically terminated; and 12.2.2 the Applicant shall destroy the Materials or otherwise render them permanently inaccessible and confirm in writing to access@ukbiobank.ac.uk that this has been done. For the avoidance of doubt, the Applicant shall not be required to destroy Results Data or Other Data subject to the provisions of this MTA being complied with.
    * **対応するEGAの条文（英）:** 15. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements.
        * **比較結果:** 一致
        * **判断理由（日）:** UKBBとEGAの両方の条文は、契約終了時に申請者（ユーザー機関）がデータを破棄することを要求している。UKBBは「Materials」の破棄に焦点を当て、EGAは「Data」の破棄に焦点を当てているが、主題は一致している。
    * **対応するNIHの条文（英）:** 8.c. Effect of Termination: [Insert the Registry's requirement for post-termination activities, e.g., will Data need to be returned or destroyed, can Researcher continue using the Data for a limited period].
        * **比較結果:** 部分一致
        * **判断理由（日）:** NIHの条文は終了後の措置について言及しているが、具体的な内容（破棄、返却など）は示されていないため、部分一致とした。

* **UKBBの条文（英）:** 12.3 Without prejudice to the foregoing and to any other rights or remedies that UK Biobank may have, UK Biobank may take the following steps if there is a breach that entitles UK Biobank to terminate this MTA under clause 12.1: 12.3.1 it may prohibit the Applicant PI, Applicant Researchers and any other researchers from the Applicant Institution from accessing any further Materials from within the UK Biobank resource for an indefinite period of time; and/or 12.3.2 it may elect to inform the relevant personnel within the defaulting Applicant Institution, funders of the defaulting Applicant PI and/or governing or other relevant regulatory bodies.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 12.4 Notwithstanding termination of this MTA for any reason, the provisions of clauses 2, 3, 4, 5, 7, 8, 9, 10, 12, 13, 14, 16 and 17 shall continue in force in accordance with their respective terms.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 12.5 Termination or expiry of this MTA shall not affect the rights and obligations of the parties accrued at the date or termination or expiry.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

***

### 条文番号の対応関係

| UKBBの条文番号 | EGAの条文番号 | NIHの条文番号 |
| :--- | :--- | :--- |
| 10.1 | なし | 4 |
| 10.2 | 6 | 4 |
| 10.3 | なし | なし |
| 10.4 | 6 | なし |
| 10.5 | なし | なし |
| 11.1 | なし | 8.a |
| 11.2 | なし | なし |
| 11.3 | なし | なし |
| 12.1 | 15 | 8.b |
| 12.2 | 15 | 8.c |
| 12.3 | なし | なし |
| 12.4 | なし | なし |
| 12.5 | なし | なし |